MAPT and tauopathy: Thus, tau has been an important target in therapeutic development for AD and primary tauopathies, with several immunotherapies, antisense oligonucleotides, and aggregation inhibitors under clinical trials (DeVos et al., 2017; Congdon and Sigurdsson, 2018; Boxer et al., 2019, 2020; Ayalon et al., 2021; Grossman, 2021; Mullard, 2021; Novak et al., 2021).